LABORATOIRES JUVISE PHARMACEUTICALS : revenue, balance sheet and financial ratios

In 2024, LABORATOIRES JUVISE PHARMACEUTICALS achieves revenue of 160.6 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +28.9%. Vs 2023, growth of +43% (112.5 M€ -> 160.6 M€). After deducting consumption (11.5 M€), gross margin stands at 149.1 M€, i.e. a rate of 93%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 76.0 M€, representing 47.3% of revenue. Warning negative scissor effect: despite revenue change (+43%), EBITDA varies by +32%, reducing margin by 4.0 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Net income is negative at -22.5 M€ (-14.0% of revenue), which will impact equity.

The debt ratio (= Financial debt / Equity x 100) stands at 2233%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 4%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 13.4 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 20.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

The liquidity ratio (= Current assets / Current liabilities) stands at 176.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 57.2x. Operating income very largely covers interest expenses: high safety margin.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 80 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 142 days. Excellent situation: suppliers finance 62 days of the operating cycle (retail model). Inventory turnover is 81 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 151 days of revenue, i.e. 67.3 M€ to permanently finance.

Based on 124 transactions of similar company sales (all years), the value of LABORATOIRES JUVISE PHARMACEUTICALS is estimated at 46 241 505 € (range 22 751 912€ - 160 470 616€). With an EBITDA of 75 957 481€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.